SecBot SecBot
8-K ·Filed Jul 2, 2026

PYXS

Pyxis Oncology, Inc.
MIXED
Impact 6/10
Horizonweeks Processed4mo ago SEC0001193125-26-294613
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ◆ Mixed

The capital raise removes near-term cash runway risk through Q2 2027, allowing investors to focus on upcoming MICVO clinical catalysts in Fall 2026. However, the dilutive structure and warrant overhang could pressure shares near term. Monitor stock price relative to the $2.551 placement price and watch for insider or warrant holder selling patterns after the resale registration becomes effective.

DirectionMixed
Confidencehigh
Horizonweeks

PYX-201

◆ Mixed Named in this 8-K
Impact
Phase
Phase 1 / Phase 1/2
Time to market
At least 2-3 years, assuming Phase 3 trial (planned mid-2027) succeeds and leads to an NDA filing. No regulatory filing has occurred yet.
Next catalyst
None dated

What to watchThe next near-term catalyst is the EORTC-NCI-AACR late-breaking oral presentation (Nov 18-20, 2026), though the top-line data has already been disclosed. The true binary events are: Q4 2026 updated combo data, Q1 2027 End-of-Phase 2 meeting with FDA, and H1 2027 overall survival data from the monotherapy study, any of which could drive major moves. The $3.50 common warrant exercise trigger (requiring both shareholder approval and OS data) creates an additional overhang that could cap upside until clarity emerges.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.63
T+0 close · Jul 2, 2026 · via day close
Latest settled
+10.27%
T+60 · $2.90
Vs SPY
+6.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $2.63entry
  2. T+1 · 4mo ago −6.46%α −7.34% · $2.46
  3. T+5 · 4mo ago +0.38%α −0.55% · $2.64
  4. T+20 · 4mo ago +9.13%α +9.54% · $2.87
  5. T+60 · 7w ago +10.27%α +6.70% · $2.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pyxis Oncology entered into a securities purchase agreement for a $50 million private placement (plus up to $64 million from warrants) led by BVF Partners, issuing 19.6 million shares at $2.551/share and warrants exercisable at $3.289. Proceeds extend cash runway into Q2 2027 and fund MICVO clinical milestones. The financing is dilutive (~28% of current float) but provides critical capital for a pre-revenue biotech.

Key Financial Metrics

Offering Size
$50.0M
Dilution
28%

Key Facts

  • $50M upfront gross proceeds from sale of 19,600,153 shares at $2.551/share
  • Warrants to purchase up to 19,600,153 shares at $3.289/share, exercisable after MICVO data disclosure or Oct 1, 2026, expiring July 2, 2029
  • Potential total gross proceeds of ~$114M if warrants fully exercised for cash
  • Cash runway extended into Q2 2027
  • BVF Partners L.P., GordonMD Global Investments, RTW Investments, and Coastlands Capital LP participated
  • MICVO (micvotabart pelidotin) Phase 1 monotherapy data expected Fall 2026; Phase 1/2 combination data expected Q4 2026

Financial Impact

$50M gross proceeds upfront, ~28% dilution based on estimated pre-offering shares outstanding, plus additional dilution risk from potential warrant exercise

cash runwaydilutionshare count

Risk Factors

  • Significant dilution from share issuance and potential warrant exercise
  • Warrant overhang with exercise price close to market could pressure stock if data disappoints
  • Clinical development risk for MICVO; delayed or negative data could impair capital position

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-294613
Document: pyxs-ex10_2.htm0001193125-26-294613
Document: pyxs-ex4_1.htm0001193125-26-294613
Document: pyxs-20260630.htm0001193125-26-294613
Document: pyxs-ex99_1.htm0001193125-26-294613
Document: 0001193125-26-294613-index-headers.html0001193125-26-294613
Document: 0001193125-26-294613-index.html0001193125-26-294613
Document: 0001193125-26-294613.txt0001193125-26-294613

Track record

25 reports on PYXS

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
  3. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
  5. Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
  6. Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
  7. Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
  8. Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
  9. Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
  10. Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 2, 2026